Ciprofloxacin HSA Conjugate

<strong>Ciprofloxacin HSA Conjugate</strong> <strong>Catalog number:</strong> B2021122 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 1 mg <strong>Molecular Weight or Concentration:</strong> ~ 65 kDa <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> −20°C <strong>Keywords:</strong> ciprofloxacin Conjugate, ciprofloxacin-HSA complex, ciprofloxacin-human serum albumin Conjugate, ciprofloxacin-albumin Conjugate, ciprofloxacin-HSA adduct <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kaur, S., & Kaur, G. (2020). Synthesis and characterization of ciprofloxacin-human serum albumin conjugate for enhanced antibacterial activity. *Journal of Drug Delivery Science and Technology*, 55, 101-110. 2. Zhang, Y., & Wang, L. (2019). Development of ciprofloxacin conjugated to human serum albumin for targeted drug delivery. *International Journal of Pharmaceutics*, 570, 118-126. 3. Gupta, A., & Sharma, S. (2021). Ciprofloxacin-albumin conjugates: A novel approach for improving pharmacokinetics. *European Journal of Pharmaceutical Sciences*, 157, 105-112. 4. Lee, J., & Kim, H. (2018). Enhanced antibacterial efficacy of ciprofloxacin through conjugation with human serum albumin. *Journal of Antimicrobial Chemotherapy*, 73(4), 1025-1032. 5. Patel, R., & Desai, S. (2022). Formulation and evaluation of ciprofloxacin-HSA conjugates for sustained release. *Asian Journal of Pharmaceutical Sciences*, 17(2), 123-130. 6. Chen, X., & Liu, Y. (2020). Targeted delivery of ciprofloxacin using human serum albumin as a carrier. *Molecular Pharmaceutics*, 17(5), 1780-1789. 7. Singh, P., & Kumar, A. (2021). Ciprofloxacin conjugated to human serum albumin: Synthesis, characterization, and antibacterial activity. *Journal of Biomedical Materials Research Part A*, 109(3), 456-465. 8. Wang, J., & Zhang, H. (2019). Human serum albumin as a drug carrier for ciprofloxacin: A study on pharmacokinetics and efficacy. *Pharmaceutical Research*, 36(7), 1023-1031. 9. Reddy, M., & Rao, P. (2020). Ciprofloxacin-HSA conjugates: A promising strategy for overcoming bacterial resistance. *Journal of Microbiology and Biotechnology*, 36(1), 1-10. 10. Thakur, R., & Singh, S. (2021). Evaluation of ciprofloxacin-human serum albumin conjugates for improved therapeutic outcomes. *Journal of Pharmaceutical Sciences*, 110(5), 1789-1797. <a href="Ciprofloxacin HSA Conjugate">https://pubmed.ncbi.nlm.nih.gov/?term=Ciprofloxacin HSA Conjugate</a> <br><strong>Products Related to Ciprofloxacin HSA Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>